Newsfiscal.ai
Pyxis Oncology Announces Late-Breaking Oral Presentation of Micvotabart Pelidotin Data
· Published
Article summary
Pyxis Oncology, Inc. will present Phase 1 monotherapy data for its drug candidate micvotabart pelidotin (MICVO) at the 38th EORTC-NCI-AACR Symposium.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…